BLAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
KEYTRUDA (pembrolizumab) by Merck & Co. is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEYTRUDA (pembrolizumab) is a monoclonal antibody that blocks the Programmed Death Receptor-1 (PD-1), unleashing the immune system to attack cancer cells. It is approved across multiple solid and hematologic malignancies and represents a cornerstone of modern immuno-oncology therapy. The mechanism works by inhibiting the PD-1/PD-L1 checkpoint interaction, restoring anti-tumor T-cell function.
$0.117BPart D
PeakPeak-stage asset with established market presence generating substantial Part D volume; expect mature commercial infrastructure and focus on lifecycle extension through combinations and new indications.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
Started Dec 2026
27 enrolled
Locally Advanced Bladder Urothelial CarcinomaLocally Advanced Renal Pelvis Urothelial CarcinomaLocally Advanced Ureter Urothelial Carcinoma+10 more
Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer
Started Sep 2026
17 enrolled
Anal Squamous Cell Carcinoma
Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC
Started Sep 2026
56 enrolled
Urothelial Bladder Cancer
Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer
Started Sep 2026
50 enrolled
TNBC - Triple-Negative Breast CancerTNBCEarly Stage Triple-Negative Breast Carcinoma
Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Started Aug 2026
138 enrolled
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Worked on KEYTRUDA at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.